The new Sassun-Mayo staging system, which integrates tumor deposit and lymph node counts, improves prognostic accuracy for patients with colon cancer compared with the standard American Joint ...
The FDA has approved atezolizumab plus chemotherapy as an adjuvant treatment for patients aged 2 years and older with stage ...
Genentech, part of Roche Group (USOTC:RHHBY), has received FDA approval for Tecentriq in combination with chemotherapy for a ...
The Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy on Oct. 8 as an ...
The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...
Morning Overview on MSN
Atezolizumab plus chemo won FDA approval for some stage III colon cancers
On Oct. 8, 2026, the Food and Drug Administration approved atezolizumab, sold as Tecentriq by Genentech, together with chemotherapy for adults and children as young as two with Stage III colon cancer ...
Colorectal cancer in young people is often diagnosed at an advanced stage, with researchers finding most patients age 21 or ...
The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results